Studies have shown that eating a diet high in soluble fiber may help to eliminate C. diff. (and other types of bacterial ...

C. diff is suspected of causing almost all intestinal infections following therapy with antibiotics. Older people are at greater risk of getting C. diff because they are more likely to be ...

Clostridioides difficile infection is a major healthcare-associated infection, causing significant morbidity and mortality, ...

Signs of inflammatory bowel disease (IBD ... collection period involved changes in treatment models for IBD and C difficile infection, which may have influenced the results.

difficile infection. Another 25 bacteria were positively correlated with C. difficile, meaning that they were present ... microbial interactions in other conditions like inflammatory bowel disease ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

diff, reducing and hopefully eradicating the infection. Ferring acquired ... working in partnership with Roche on C. diff as well as inflammatory bowel disease (IBD), as well as Vedanta, Seres ...

shows promise in mitigating Clostridioides difficile (C. difficile) infection, particularly those resistant to antibiotics. A pilot study conducted in a mouse model suggests that tagatose could ...

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a ...

Clostridium difficile (C.diff) intestinal infections are included because hospital staff can prevent the C. diff bacterium from being transmitted to patients. The bacterium causes diarrhea and ...

It’s thought that the population of microbes in the gut, known as the gut microbiome, could be affecting a range of diseases from Irritable Bowel ... a recurrent C.difficile infection that ...

new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC ...